Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19877231 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL2248826 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL17920095 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL19798977 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL17756103 | 0.89 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL20411051 | 0.88 | NR1H2 (0.43) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL17032294 | 0.88 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL7030224 | 0.88 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL26093109 | 0.85 | MEN1 (0.41) | ALDH1A1MEN1KMT2ATSHRMAPT | |
| SCHEMBL12723118 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3496716-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| WO-2018034917-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ALDH1A1 1462/4885MEN1 2808/4885KMT2A 3447/4885 |
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | CYP27A1, CYP7A1, CYP7B1 | ALDH1A1 432/4885MEN1 3340/4885KMT2A 3614/4885 |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | ALDH1A1 355/4885MEN1 2059/4885KMT2A 4082/4885 |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | ALDH1A1 334/4885MEN1 1945/4885KMT2A 4179/4885 |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | CYP27A1, CYP7B1, SLC10A1 | ALDH1A1 398/4885MEN1 1846/4885KMT2A 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.